Oncolytics Expects Interim REO 033 Data by Year-End; FDA Aligns on Accelerated Approval Path
ONCY is trading near its 52-week low of $0.642 (6.4% above the low).
Summary
Oncolytics reported accelerating enrollment in its REO 033 colorectal cancer study and expects interim data by year-end 2026. FDA alignment provides a potential path to accelerated approval based on objective response rate.
Key Events · Product Development and Regulatory · ONCY
-
REO 033 Enrollment Accelerating
Substantially all planned clinical sites for Part A are now activated, with multiple patients enrolled. Part A is expected to enroll approximately 60 patients randomized between pelareorep + FOLFIRI + bevacizumab and FOLFIRI + bevacizumab alone.
-
Interim Data Expected by Year-End 2026
Company expects to have sufficient Part A data to provide an interim clinical update by year-end 2026, based on the number of evaluable patients enrolled by the end of October.
-
FDA Aligns on Accelerated Approval Path
FDA alignment provides a potential path to accelerated approval based on objective response rate, with progression-free survival providing the basis for potential full approval. Part A data will inform the final size and execution of the potential pivotal Part B expansion.
-
REO 022 Historical Efficacy Data
Prior REO 022 study showed ORR of 33% vs historical benchmark of ~6–11%, median PFS of 16.6 months vs ~5.7 months, and median OS of 27.0 months vs ~11.2 months. REO 033 is designed to test these signals prospectively in a randomized setting.
Analysis · ONCY · Life Sciences
Oncolytics announced that nearly all planned clinical sites for Part A of its randomized REO 033 colorectal cancer study are now activated, with multiple patients enrolled. The company expects to report interim data by year-end 2026 based on patients enrolled by the end of October. Critically, the FDA has aligned on a potential accelerated approval path using objective response rate, with progression-free survival supporting full approval. This is a meaningful regulatory milestone for a company facing a Nasdaq delisting notice and going-concern doubts — a clear path to registration could materially improve its financing and strategic options.
How filings like this one have moved
In the 30 days to Nov 1, 2026, 32.4% of the 1981 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ONCY was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $87.1M. The 52-week trading range was $0.64 to $1.51. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.